Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innate Pharma S.A. ADR (IPHA)

Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,409
  • Shares Outstanding, K 92,189
  • Annual Sales, $ 21,770 K
  • Annual Income, $ -53,530 K
  • EBIT $ 0 M
  • EBITDA $ -54 M
  • 60-Month Beta -0.08
  • Price/Sales 7.20
  • Price/Cash Flow N/A
  • Price/Book 26.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6300 +7.36%
on 12/26/25
2.0100 -12.94%
on 12/01/25
-0.2000 (-10.26%)
since 11/28/25
3-Month
1.6300 +7.36%
on 12/26/25
2.4250 -27.84%
on 11/10/25
-0.1800 (-9.33%)
since 09/30/25
52-Week
1.6000 +9.37%
on 01/15/25
2.6300 -33.46%
on 07/30/25
-0.2000 (-10.26%)
since 12/30/24

Most Recent Stories

More News
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers...

IPHA : 1.7500 (+0.57%)
Innate Pharma Releases Its 2026 Financial Calendar

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2026 financial calendar: ...

IPHA : 1.7500 (+0.57%)
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers...

IPHA : 1.7500 (+0.57%)
Innate Pharma to Present at Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces its participation in the Jefferies...

IPHA : 1.7500 (+0.57%)
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome ...

IPHA : 1.7500 (+0.57%)
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of systemic...

IPHA : 1.7500 (+0.57%)
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference...

IPHA : 1.7500 (+0.57%)
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation...

IPHA : 1.7500 (+0.57%)
Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA)

Goldman Sachs analyst maintained a Hold rating on Innate Pharma today. The company’s shares closed yesterday at $1.95.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

IPHA : 1.7500 (+0.57%)
IPHYF : 2.1550 (+13.12%)
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF)

In a report released yesterday, from Goldman Sachs maintained a Hold rating on Innate Pharma SA, with a price target of €2.23. The company’s shares closed last Thursday at $2.00.Elevate Your Investing...

IPHA : 1.7500 (+0.57%)
IPHYF : 2.1550 (+13.12%)

Business Summary

Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.

See More

Key Turning Points

3rd Resistance Point 1.8999
2nd Resistance Point 1.8499
1st Resistance Point 1.8000
Last Price 1.7500
1st Support Level 1.7001
2nd Support Level 1.6501
3rd Support Level 1.6002

See More

52-Week High 2.6300
Fibonacci 61.8% 2.2365
Fibonacci 50% 2.1150
Fibonacci 38.2% 1.9935
Last Price 1.7500
52-Week Low 1.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar